Biological Parameters Changes After Autologous Blood Transfusion of Red Blood Cells (200 Ml) in Healthy Volunteers.

NCT ID: NCT03889834

Last Updated: 2024-09-26

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-01-25
• Study Completion Date: 2025-08-31

Brief Summary

The purpose of this study is to evaluate if differences between samples of subjects obtained before autologous blood transfusion or samples of non-transfused subjects and samples of subjects after autologous blood transfusion can be identified. Analyses performed will focus on the morphological and biochemical parameters of red blood cells and associated microparticles. The final goal would be to find markers of autologous blood transfusion, that could be used to identify such doping practice.

Detailed Description

Methodology and study design:

Pr Olivier Hermine, coordinator of the laboratory of Excellence GR-EX regrouping EFS (Etablissement Français du Sang) and INSERM (Institut National de la Santé et de la Recherche Médicale) partners, and leader of the Centre d'Investigation Clinique (CIC) Necker (Hospital Necker, Paris, France) will assure the promotion of the clinical study for Paris Hospital consortium AP-HP (assistance Publique-Hôpitaux de Paris).

To reproduce two potential scenarios of autologous transfusion by an athlete, 1 bag of blood packed red blood cells (after leuko deprivation and centrifugation) will be either stored at 4°C or frozen at -80°C after addition of 40% w/v glycerol. Reinfusion will be performed 31 days later.

A clinical randomized double-blinded two-phase study will be conducted. Volunteers will be separated in 3 groups:

• Group 1: Volunteers with regular sports activities without Autologous Blood Transfusion (ABT)T (n=10)
• Group 2: Volunteers with regular sports activities receiving a 200ml ABT with refrigerated blood (n=10)
• Group 3: Volunteers with regular sports activities receiving a 200ml ABT with frozen blood (n=10)

To ensure volunteers safety, collection, preparation and pretransfusion blood testing will be performed by EFS (Versailles, France). ABT as well as collection of samples will be performed at the CIC Necker (Paris, France). Blood samples will be collected before blood removal, the day of the ABT just before reinfusion and after 3 hours, 8 hours, 24 hours and 48 hours post-ABT. To perform all the experiments 25ml blood (4x 5 ml BD Vacutainer EDTA tubes) will be taken at each time point:

1 will be dispatched to the French anti-doping laboratory (LADF) for haematological analysis (Orsay, France), 2 to the EFS (Créteil, France) for RBC and MPs morphological characterization and quantification (using antigen markers, band 3 on the surface of MPs), 2 to INTS for MPs isolation, characterization (band 3 on the surface of MPs and RBC) and for proteomic analysis and Western-Blot.

Conditions

The Focus is on the Detection of the Consequences of Autologous Blood Transfusion in Healthy Volunteers

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Autotransfusion: blood stored at 4 ° C

Intervention: Autologous Blood Transfusion of packed red blood cells (200 ml) stored at 4 ° C for 31 days

Group Type: EXPERIMENTAL

Autologous Blood Transfusion

Intervention Type: PROCEDURE

Autotransfusion of packed red blood cells (200 ml) stored at 4 or -80°C for 31 days

Autotransfusion: blood stored at -80°C

Intervention: Autologous Blood Transfusion of packed red blood cells (200 ml) stored at -80°C for 31 days

Group Type: EXPERIMENTAL

Autologous Blood Transfusion

Intervention Type: PROCEDURE

Autotransfusion of packed red blood cells (200 ml) stored at 4 or -80°C for 31 days

Controls not transfused

no transfusion

Group Type: OTHER

No transfusion

Intervention Type: OTHER

no transfusion

Interventions

Autologous Blood Transfusion

Autotransfusion of packed red blood cells (200 ml) stored at 4 or -80°C for 31 days

Intervention Type: PROCEDURE

No transfusion

no transfusion

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Male between 18 and 35 years old
• Without health problem nor disease requiring regular medical treatment
• Free from any intercurrent acute pathology over 7 days
• Healthy volunteers who have regularly sport activity, able to have blood sample and is out-of-competition during the research
• Subject who did not practice a competition (or exhaustive training ) 3 days before the blood sample and the autotransfusion
• Affiliated to a social security regimen

Exclusion Criteria

• Subject with contraindication for drawing blood
• Subject with medical pathology contraindicating sport practice
• Subject under treatments or drugs in the list of products prohibited for sports practice and competitions, in particular erythropoeitins and erythropoiesis-stimulating agents (updated list of World Anti-Doping Agency https://www.wada-ama.org/fr/liste-des-restrictions).
• Subject with physical or mental disability or restriction of liberty that would prevent autotransfusion
• Subject without a social security regimen
• Subject under guardianship or curatorship
• Subject participating in any Interventional study
• Positive HIV and/or hepatitis serology
• Discovery of a hematological disease

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 35 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Laboratoire antidopage français (LADF)

UNKNOWN

Sponsor Role: collaborator

World Anti-Doping Agency

OTHER

Sponsor Role: collaborator

GR-Ex executive comitee

UNKNOWN

Sponsor Role: collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

Sponsor Role: collaborator

Etablissement Français du Sang

OTHER

Sponsor Role: collaborator

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Olivier HERMINE, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Assistance Publique-Hôpitaux Paris

Locations

EFS de Versailles, centre de soins

Le Chesnay-Rocquencourt, , France

Site Status: RECRUITING

Countries

France

Central Contacts

Olivier Hermine, MD, PhD

Role: CONTACT

olivier.hermine@aphp.fr

+33 (0)1 44 49 51 98

Jinmi BAEK, Master

Role: CONTACT

jinmi.baek@aphp.fr

: +33 (0)1 42 19 28 49

Facility Contacts

RAOULT-VALETTE Laurence, MD

Role: primary

Other Identifiers

K180405J

Identifier Type: -

Identifier Source: org_study_id